Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB MF and SS

Brief Summary:

This phase I trial identifies the best dose, possible benefits, and/or side effects of duvelisib in combination with nivolumab in treating patients with stage IIB-IVB mycosis fungoides and Sezary syndrome. Duvelisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving duvelisib in combination with nivolumab may work better than giving each of these drugs individually, or treating with the usual approach in patients with mycosis fungoides and Sezary syndrome.


To determine the recommended phase II dose (RP2D) or maximum tolerated dose (MTD) of the combination of duvelisib with nivolumab in patients with advanced mycosis fungoides/Sezary syndrome (MF/SS).

Website: https://clinicaltrials.gov/ct2/show/NCT04652960?term=10347&draw=2&rank=2

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. 

Please refer to this study by its ClinicalTrials.gov identifier: NCT04652960


National Cancer Institute (NCI)

Information provided by (Responsible Party):

National Cancer Institute (NCI)


Participating Locations:

Mayo Clinic - Florida
Jacksonville, FL, United States
Principal Investigator
Allison C. Rosenthal, DO